Oncovir, Inc. HomeHiltonol BackgroundClinical Trials About OncovirOncovir, Inc is a pharmaceutical corporation dedicated to the development of nucleic-acid-based clinical therapies for cancer, infectious, immune, and degenerative disorders. Oncovir promotes Hiltonol (poly-ICLC) as an experimental vi...

Oncovir, Inc. Clinical Trials HomeHiltonol BackgroundClinical Trials Hiltonol plus Dendritic Cell Vaccine for Recurrent GlioblastomaApril, 2007. Oncovir is pleased to announce the opening of a new clinical trial of Hiltonol plus a dendritic cell vaccine targeting specific brain tumor antigens in pat...

Oncovir, Inc. Hiltonol (Poly-ICLC) Background HomeHiltonol BackgroundClinical Trials Activating the Natural Host DefenseHiltonol (Poly-ICLC) and Malignant Brain TumorsAndres M. Salazar MD*Oncovir, Inc BackgroundOver 45 years ago Isaacs and Lindenman discovered a substance produced by virally infecte...

Oncovir, Inc. HomeHiltonol BackgroundClinical Trials About OncovirOncovir, Inc is a pharmaceutical corporation dedicated to the development of nucleic-acid-based clinical therapies for cancer, infectious, immune, and degenerative disorders. Oncovir promotes Hiltonol (poly-ICLC) as an experimental vi...